) has entered into a partnership with The Scripps Research
Institute (TSRI) to fund research and offer publication access to
TSRI researchers' discoveries for the synthesis and analysis of
potential drugs. Through this alliance, the partners promise to
eliminate the delay between the invention of novel reagents and
reliable, widespread applications for drug discovery.
The partnership, involving a research institute and a reagents
company, is the first-of-its- kind. Following the previous
partnerships with Janssen Pharmaceuticals and
Bristol-Myers Squibb Company
), this is TSRI's third major alliance as part of the new
targeted partnership strategy. Last year, Sigma-Aldrich and TSRI
established a partnership to produce in bulk a toolkit of ten
novel zinc-based salts discovered in the Baran lab.
According to the present deal, Sigma-Aldrich will fund
developments of novel reagents from six TSRI research labs led by
eminent professors including Nobel Laureate K. Barry Sharpless.
The discoveries of the synthesis and analysis of potential drugs
by the TSRI chemists and scientists will be immediately published
by Sigma-Aldrich via a master licensing agreement.
TSRI will be utilizing the funds to expand its basic research
capacity. This will also help chemists and scientists, who do not
have a background in chemical synthesis, to now have unrestrained
access to new reagents for the translational research community
and implement novel reagents in their research.
The partnership will also bring an end to the hurdles faced by
the researchers to get the novel reagents inventions receive
reliable and widespread access to those reagents for the
translational research community. Thus, the initiative taken by
TSRI will open a myriad of novel technologies.
Sigma-Aldrich expects the partnership with TSRI to reinforce
its strategy of broadening the research portfolio of innovative
products and tools used by the translational research
Headquartered in La Jolla, Calif., TSRI is a non-profit ,
independent American medical research organization that focuses
on research and education in the biomedical sciences. TSRI is
famous for its remarkable contributions to science and health,
including its role in laying the foundation for new treatments
for cancer, rheumatoid arthritis, hemophilia, and other
Sigma-Aldrich, which is a prominent player in the specialty
chemical space along with
American Vanguard Corp.
), is a Life Science and High Technology company whose
biochemical, organic chemical products, kits and services are
used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the
diagnosis of disease and as key components in pharmaceutical,
diagnostics and high technology manufacturing.
Sigma-Aldrich currently maintains a Zacks Rank #4 (Sell).
AMER VANGUARD (AVD): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
FERRO CORP (FOE): Free Stock Analysis Report
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.